Overview

OCR002-SP103 - Oral Immediate Release Study

Status:
Completed

Trial end date:
2017-12-31

Target enrollment:

Participant gender:

Summary

This is an open-label Phase 1, 2-part, crossover study in approximately 33 adult subjects (12 subjects in Part 1 and 21 subjects in Part 2), with varying degrees of cirrhosis with analysis of pharmacokinetic (PK) data after Part 1 to guide dose regimen selection and PK sampling time points for OCR-002 in Part 2.

Phase:

Phase 1

Details

Lead Sponsor:

Ocera Therapeutics
Ocera Therapeutics, Inc.

Treatments:

Pharmaceutical Solutions
Phenylacetic acid